CūtisCare Increasing Awareness This National Diabetes Month To Save Limbs and Lives

CūtisCare, a leading provider of wound care management services to hospitals and physicians, is continuing our fight this month to raise awareness regarding diabetes and the available treatment options to help save limbs and lives.

According to the CDC, diabetes currently adversely impacts the lives of approximately 34 million Americans, and that number is continuing to increase each year. About 25% of people with diabetes will develop foot ulcers, and 1% end up with an amputation in their lifetime. However, as many as 85% of potential amputations can be avoided when advanced modalities, such as hyperbaric oxygen therapy, or HBOT, are added to a treatment plan.

There is good news on the horizon though. Many of these amputations are preventable. HBOT is one therapy that is showing great promise. Louis Pilati MD, CutisCare’s Medical Advisory Board Member, expounds on the manifold benefits of HBOT for patients with Wagner Grade 3 or higher:

The physiologic effect of hyperbaric oxygen treatment of the diabetic foot patient is to reverse the impediments caused by hypoxemia or below-normal level of oxygen in your blood. Hyperbaric oxygen increases the dissolved oxygen and the amount of oxygenated plasma dissolved in tissue. It also increases reactive oxygen and nitrogen species to increase growth factor synthesis, stem cell proliferation, diminished inflammatory response, and enhanced white blood cell killing of bacteria.

Thousands of hospitals and healthcare practices are still not equipped to provide limb-saving treatments, so many patients with diabetes are not aware that these treatment options exist. As a partner to the nation’s leading healthcare facilities, the team at CūtisCare is dedicated to bringing awareness to early prevention methods those with diabetes can take to prevent amputations that can result from foot ulcers and other large wounds. Visit cutiscareusa.com, as well as our social media channels, throughout November to access educational resources highlighting this life-saving treatment option, a foot care guide for how to reduce complications, take a Diabetes Risk Test, or even to find a treatment provider near you.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version